Dementia Treatment Global Market Report 2025

The dementia treatment market size has grown strongly in recent years. It will grow from $18.32 billion in 2024 to $20.14 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth during the historic period can be attributed to factors such as the aging population, improved diagnosis rates, greater awareness of dementia, the expansion of healthcare infrastructure, and increased government funding for dementia research and treatment.

The dementia treatment market size is expected to see strong growth in the next few years. It will grow to $29.12 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth during the forecast period can be attributed to factors such as increased healthcare expenditure, a higher prevalence of chronic diseases, more clinical trials, growth in the pharmaceutical industry, and rising rates of Alzheimer's disease. Key trends in the forecast period include advancements in scientific research, the use of artificial intelligence and machine learning for diagnosis and treatment management, the development of new drugs and therapies, increased investment in biotechnology, and progress in personalized treatment approaches.

The rising prevalence of neurodegenerative disorders is expected to drive the growth of the dementia treatment market in the coming years. Neurodegenerative disorders, which involve the progressive degeneration and loss of nerve cells, lead to impairments in movement, cognition, or both. This increase in neurodegenerative disorders is largely attributed to the aging population, as longer life expectancy raises the risk of age-related conditions such as Alzheimer's and Parkinson's disease, with age being the primary contributing factor. A deeper understanding of neurodegenerative disorders enhances dementia treatment by enabling more accurate diagnoses and targeted therapies, allowing for a more personalized and effective approach to managing symptoms. For instance, according to a report published in April 2024 by the Alzheimer's Association, approximately 6.9 million Americans aged 65 and older were affected by Alzheimer's dementia, with projections suggesting this number will double to 13.8 million by 2060. As a result, the growing prevalence of neurodegenerative disorders will significantly drive the growth of the dementia treatment market.

Leading companies in the dementia treatment sector are concentrating on developing advanced technological solutions, such as virtual reality (VR) training programs, to replicate intricate and varied scenarios. VR training programs are immersive, computer-generated experiences that provide individuals with the opportunity to practice and refine their skills in a controlled, interactive, and realistic virtual setting. For example, in September 2024, Otsuka Pharmaceutical Co. Ltd., based in Japan, collaborated with Jolly Good Inc., a medical technology company from Japan, to introduce FACEDUO, a VR training program tailored for dementia care. This interactive VR tool, overseen by medical professionals, assists caregivers, including family members, in understanding the emotions and behaviors of individuals with dementia. By simulating real-life situations, the program enables caregivers to respond more effectively to the specific needs of dementia patients. Its primary goal is to enhance caregiving abilities and foster empathy for more impactful support.

In April 2024, Rippl, a US-based provider specializing in dementia care, acquired Kinto for an undisclosed sum. This acquisition aims to expedite the development of Rippl's dementia care platform by integrating artificial intelligence (AI)-driven solutions to enhance patient care. Kinto, a US-based AI healthcare company, focuses specifically on dementia care.

Major players in the dementia treatment market are Roche Holding AG, AbbVie Inc., Sanofi S.A., Eli Lilly and Company, Amgen Inc., Biogen Inc., Eisai Co. Ltd., Merz Pharmaceuticals GmbH, Acadia Pharmaceuticals Inc., Intra-Cellular Therapies Inc., Cerevance Inc., Retro Biosciences Inc., AviadoBio Ltd., MapHabit Inc., Neuvivo Inc., Harmonic Health Inc., Rippl Care Inc., Isaac Health Inc., EmTech Care Labs Inc., and LifeBio Inc.

North America was the largest region in the dementia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dementia treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the dementia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Dementia treatment involves a combination of medical, psychological, and supportive approaches aimed at managing symptoms and slowing the progression of the condition, which is characterized by memory loss, cognitive decline, and difficulty with reasoning. Early detection of dementia enables more effective intervention and facilitates the preparation of long-term care plans. Tailored treatment strategies, based on the specific type and stage of dementia, can enhance the quality of life for those affected.

The primary treatment options for dementia include antipsychotics, cholinesterase inhibitors, memantine, and others. Antipsychotic medications are prescribed to manage behavioral and psychological symptoms in dementia patients, such as aggression, agitation, and hallucinations. These medications are used to treat various forms of dementia, including Alzheimer's disease dementia, vascular dementia, Lewy body dementia, frontotemporal dementia, Parkinson's disease dementia, and others. Antipsychotics can be administered via oral tablets, transdermal patches, or injectables, and are used for managing mild, moderate, and severe stages of dementia. They are typically distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The dementia treatment market research report is one of a series of new reports that provides dementia treatment market statistics, including dementia treatment industry global market size, regional shares, competitors with a dementia treatment market share, detailed dementia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the dementia treatment industry. This dementia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The dementia treatment market consists of revenues earned by entities by providing services such as medication management, cognitive therapy and stimulation, and behavioral and psychological support. The market value includes the value of related goods sold by the service provider or included within the service offering. The dementia treatment market also includes sales of memory-enhancing medications, nutritional supplements, cognitive stimulation tools, and medical alert systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.